

# Lars Viktrup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6577344/publications.pdf>

Version: 2024-02-01

19  
papers

658  
citations

840776

11  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 37.	7.4	145
2	<p></p>Nerve Growth Factor Signaling and Its Contribution to Pain</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 1223-1241.	2.0	104
3	Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 800-810.	0.9	98
4	Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. <i>Pain</i> , 2019, 160, 2210-2220.	4.2	78
5	Long-term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1167-1177.	5.6	39
6	Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 110-119.	1.3	35
7	Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. <i>Pain</i> , 2020, 161, 2068-2078.	4.2	34
8	Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 1202-1213.	1.3	31
9	Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies. <i>Postgraduate Medicine</i> , 2021, 133, 879-894.	2.0	30
10	Pain severity and healthcare resource utilization in patients with osteoarthritis in the United States. <i>Postgraduate Medicine</i> , 2021, 133, 10-19.	2.0	18
11	Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United States. <i>Journal of Pain Research</i> , 2020, Volume 13, 3415-3425.	2.0	17
12	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. <i>Journal of Rheumatology</i> , 2022, 49, 615-621.	2.0	8
13	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. <i>European Journal of Pain</i> , 2022, 26, 648-667.	2.8	7
14	General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, <sc>Placebo-controlled</sc> Trials. <i>Arthritis Care and Research</i> , 2022, 74, 918-928.	3.4	5
15	Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study. <i>Pain Management</i> , 2021, , .	1.5	3
16	Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States. <i>Pain and Therapy</i> , 2022, 11, 191-208.	3.2	3
17	Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 353-363.	1.1	2
18	Factors associated with physician-reported treatment status of patients with osteoarthritis pain. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, .	1.9	1

#	ARTICLE	IF	CITATIONS
19	Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study. Surgical Technology International, 2021, 38, 467-477.	0.2	0